Establishment Labs Holdings Inc.

NASDAQ•ESTA

CEO: Mr. Juan Jose Chacon Quiros

板块: Healthcare

行业: Medical - Devices

上市日期: 2018-07-19

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

联系方式

Building B15 and 25, Coyol Free Zone, Alajuela, Costa Rica

506-2434-2400

www.establishmentlabs.com

市值

$1.84B

市盈率 (TTM)

-36.5

23.7

股息率

52周最高

$83.31

52周最低

$28.67

52周范围

63%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基于 9 年期基本面

疲弱 • 2.2 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2017-2025

财务仪表盘

Q4 2025 数据

营业收入

$64.62M+0.00%

近4季度走势

每股收益

-$0.09+0.00%

近4季度走势

自由现金流

-$2.43M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Revenue Growth Post-Approval Revenue reached $211.1M USD, increasing 27.2% driven by US market penetration post-approval.

US Market Sales Surge US market sales reached $45.6M USD for the year, following September 2024 FDA approval.

Gross Margin Improvement Gross margin increased to 69.3% from 66.0% due to higher selling prices in the United States.

Net Loss Significantly Narrows Net loss significantly narrowed to $51.1M USD, an improvement from the $84.6M USD loss reported previously.

关注风险

Sole Silicone Supplier Risk Reliance on sole silicone supplier Avantor presents risk as they plan to not automatically renew the supply agreement.

Continued Operating Losses Company incurred losses to date; achieving profitability depends on Motiva Implants commercial success and scaling.

Rising Operating Expenses Operating expenses rose significantly, with SG&A increasing 18.1% to $165.1M USD, impacting cost control.

Implant Safety Scrutiny Negative publicity and safety concerns regarding breast implants could harm reputation and reduce overall market demand.

前瞻展望

Preservé US Market Expansion Preservé launch continues through 2025, targeting a full commercial launch in the United States expected in 2026.

Elevated R&D Spending R&D expenses remain elevated for the decade-long post-approval study and advancing new product pipeline initiatives.

New CEO Strategy Execution New CEO appointed in May 2025; focus remains on executing US strategy and long-term growth priorities.

Future Capital Requirements Future capital needs depend on market adoption rates and managing significant ongoing regulatory compliance costs.

同行对比

营业收入 (TTM)

AHCO

$2.84B

+7.4%

TDOC

$2.53B

-1.5%

IART

$1.64B

+1.5%

毛利率 (最新季度)

IMTX

100.0%

+0.0pp

ATAI

100.0%

+0.0pp

TSHA

94.5%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
SYRE	$3.82B	-141.1	-29.4%	0.0%
NEOG	$1.99B	-3.3	-29.0%	0.0%
ZYME	$1.94B	-24.3	-26.0%	5.3%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

16.0%

高速增长

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月5日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据